Cyclo(prolylglycyl)
Also known as: 2,5-diketopiperazine-Pro-Gly, CPG, cyclo(L-prolyl-glycyl), cyclo(Pro-Gly), Pro-Gly DKP
Summary
Cyclo(prolylglycyl), also known as cyclo(Pro-Gly) or CPG, is a naturally occurring cyclic dipeptide (diketopiperazine) found in various organisms including bacteria, fungi, and in mammalian tissues. It has been studied for potential anxiolytic, neuroprotective, and nootropic properties in preclinical models. It is not approved for therapeutic use and remains a research-stage compound.
Mechanism of Action
Cyclo(Pro-Gly) is a diketopiperazine formed by cyclization of proline and glycine. It has been reported to modulate GABA-A receptors and interact with benzodiazepine binding sites, potentially exhibiting anxiolytic and neuroprotective properties. It may also influence dopaminergic and serotonergic neurotransmission at the CNS level.
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Anxiolytic effectNeuropsychiatricLow
- Nootropic / cognitive enhancementCognitiveLow
- AnticonvulsantNeurologicalLow
Contraindications
- Known hypersensitivity to proline or glycine derivativesAllergyHigh
Adverse Effects
- Unknown systemic effectsGeneralUnknown
Drug Interactions
- BenzodiazepinesLow
- GABAergic agentsLow
Population Constraints
- Pregnant or lactating individualsReproductiveRelative
- Pediatric populationsAgeRelative
- ElderlyAgeRelative
Regulatory Status
- European UnionUnapprovedNot EMA-approved; no IMPD or clinical trial registration identified.
- United StatesUnapprovedNot FDA-approved; no IND or clinical trial registration identified.
- United KingdomUnapprovedNot MHRA-approved; research compound only.
Not approved by any major regulatory agency (FDA, EMA, MHRA) for any therapeutic indication. Investigated exclusively in preclinical research settings.
Evidence & Sources
No sources recorded yet.